Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of vobarilizumab in active systemic lupus erythematosus
2015-000372-95Phase 2Completed
- Sponsor
- Ablynx
- Start
- Jun 2015
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Vobarilizumab dose regimen arm(s) with Placebo (2 arms). Primary endpoint: mBICLA response at Week 24. Started Jun 2015; status: completed.
02
Drugs
vobarilizumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2015-000372-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000372-95.